SCHEMBL14978752

SCHEMBL14978752

COC(=O)c1ccc(CN2CCN(C3CCNCC3)C2=O)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.41
PDE10A Q9Y233 1/20 0.41
TP53 P04637 1/20 0.40
BDKRB1 P46663 3/20 0.39
ALDH1A1 P00352 4/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALOX15 P16050 2/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HTT P42858 1/20 0.37
LMNA P02545 1/20 0.37
DPP4 P27487 2/20 0.36
ATM Q13315 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL14970184 0.94 PDE10A (0.38) BTKPDE10ATP53BDKRB1ALDH1A1
SCHEMBL14978692 0.87 BTK (0.42) BTKPDE10ATP53BDKRB1ALDH1A1
SCHEMBL14966358 0.85 TP53 (0.50) BTKPDE10ATP53KMT2ADPP4
SCHEMBL14978757 0.84 TP53 (0.55) TP53MEN1KMT2ASMN1; SMN2HTT
SCHEMBL16169609 0.82 TP53 (0.54) TP53ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL16172053 0.78 TP53 (0.42) TP53ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL23696648 0.78 CHRM3 (0.49) BDKRB1ALDH1A1CYP1A2ALOX15HSD17B10
Hydrochloric Acid SCHEMBL30097980 0.77 CHRM3 (0.48) BDKRB1ALDH1A1CYP1A2ALOX15HSD17B10
Trifluoroacetic Acid SCHEMBL14966698 0.76 GPR119 (0.43) TP53ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL14978750 0.73 GPR119 (0.39) TP53ALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
WO-2013074641-A1 PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS GPR119, UTS2R, GPR139 BTK 3635/4885PDE10A 402/4885TP53 4454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.